IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

IOL Chemicals & Pharmaceuticals Ltd

₹ 478 -4.30%
21 Sep - close price
iolcp.com BSE: 524164 NSE : IOLCP
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Pharma Segment - APIs (~46% of revenues) [1]
The company manufactures various APIs for various therapeutic areas such as Pain management, anti-diabetic, anti-platelet, anti-cholesterol and others. It is the largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share. [2] In FY22, Ibuprofen accounted for ~65% of revenues of the company's pharma segment.

Website BSE NSE
  • Market Cap ₹ 2,808 Cr.
  • Current Price ₹ 478
  • High / Low ₹ 536 / 272
  • Stock P/E 18.7
  • Book Value ₹ 257
  • Dividend Yield 0.84 %
  • ROCE 13.6 %
  • ROE 9.61 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
572 565 541 523 587 563
527 509 510 481 492 491
Operating Profit 45 56 32 43 95 73
OPM % 8% 10% 6% 8% 16% 13%
7 5 5 7 9 7
Interest 2 3 4 5 5 4
Depreciation 11 11 11 12 12 14
Profit before tax 39 47 22 33 87 61
Tax % 23% 26% 28% 28% 26% 25%
30 35 16 24 65 46
EPS in Rs 5.07 5.91 2.71 4.05 11.03 7.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 TTM
2,184 2,217 2,215
1,925 1,991 1,973
Operating Profit 259 226 242
OPM % 12% 10% 11%
17 25 28
Interest 8 16 17
Depreciation 43 46 50
Profit before tax 225 189 203
Tax % 25% 26%
168 139 150
EPS in Rs 28.56 23.70 25.60
Dividend Payout % 14% 17%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 2%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -22%
Stock Price CAGR
10 Years: 40%
5 Years: 30%
3 Years: -14%
1 Year: 31%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023
59 59
Reserves 1,334 1,449
44 80
526 435
Total Liabilities 1,962 2,022
561 752
CWIP 105 90
Investments 2 20
1,294 1,161
Total Assets 1,962 2,022

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023
93 122
-121 -120
-2 -4
Net Cash Flow -29 -2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023
Debtor Days 79 83
Inventory Days 95 77
Days Payable 95 74
Cash Conversion Cycle 79 86
Working Capital Days 78 86
ROCE % 14%

Shareholding Pattern

Numbers in percentages

10 Recently
Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023
43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 43.69% 48.19% 48.19%
6.40% 7.77% 5.96% 5.05% 2.76% 3.03% 3.14% 2.50% 2.41% 2.37% 2.43% 3.54%
0.02% 0.06% 0.06% 0.04% 0.36% 0.51% 0.04% 0.04% 0.05% 0.16% 0.23% 0.25%
49.89% 48.48% 50.29% 51.21% 53.18% 52.77% 53.13% 53.77% 53.84% 53.78% 49.15% 48.02%
No. of Shareholders 81,89086,0931,09,0921,27,8931,42,0221,45,0411,46,4371,48,9071,45,6921,43,3271,40,1771,26,004

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls